Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx...
Source: globenewswire.com
Page 2 - Presentation Highlights News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Presentation Highlights. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Presentation Highlights Today - Breaking & Trending Today
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease Vincerx hosting KOL webinar today, Saturday, December... | December 11, 2021
Source: marketscreener.com
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting
Session Dates: Friday, February 26 – Monday, March 1, 2021 Session Location: Virtual Poster Hall Poster No: L30 About ADMA Biologics, Inc. ADMA Biologics is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA) approved plasma-derived biologics for the treatment of immune deficiencies a...
Source: globenewswire.com